Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.69 +3.1%	$2.78	$2.32 ▼ $5.46	$88.80M	0.59	116,724 shs	245,095 shs
NRSN NeuroSense Therapeutics	$0.71 +0.9%	$0.78	$0.63 ▼ $2.52	$22.76M	1.56	123,521 shs	281,996 shs
SXTC China SXT Pharmaceuticals	$2.22 -4.3%	$1.86	$1.25 ▼ $1,046.98	$88.67M	1.91	135,078 shs	70,722 shs
TELO Telomir Pharmaceuticals	$1.25 -2.3%	$1.30	$1.05 ▼ $3.10	$88.03M	-0.24	87,762 shs	114,848 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+5.24%	+8.75%	-7.45%	-5.78%	-30.40%
NRSN NeuroSense Therapeutics	+1.75%	-8.03%	-15.44%	-9.75%	-71.47%
SXTC China SXT Pharmaceuticals	-1.28%	+48.72%	+46.84%	+37.28%	-99.11%
TELO Telomir Pharmaceuticals	-0.78%	+5.79%	+1.59%	+0.79%	-36.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.69 +3.1%	$2.78	$2.32 ▼ $5.46	$88.80M	0.59	116,724 shs	245,095 shs
NRSN NeuroSense Therapeutics	$0.71 +0.9%	$0.78	$0.63 ▼ $2.52	$22.76M	1.56	123,521 shs	281,996 shs
SXTC China SXT Pharmaceuticals	$2.22 -4.3%	$1.86	$1.25 ▼ $1,046.98	$88.67M	1.91	135,078 shs	70,722 shs
TELO Telomir Pharmaceuticals	$1.25 -2.3%	$1.30	$1.05 ▼ $3.10	$88.03M	-0.24	87,762 shs	114,848 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+5.24%	+8.75%	-7.45%	-5.78%	-30.40%
NRSN NeuroSense Therapeutics	+1.75%	-8.03%	-15.44%	-9.75%	-71.47%
SXTC China SXT Pharmaceuticals	-1.28%	+48.72%	+46.84%	+37.28%	-99.11%
TELO Telomir Pharmaceuticals	-0.78%	+5.79%	+1.59%	+0.79%	-36.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$8.50	215.99% Upside
NRSN NeuroSense Therapeutics	2.60	Moderate Buy	$8.50	1,105.67% Upside
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A
TELO Telomir Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest NRSN, TELO, SXTC, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2026	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/12/2026	ANIX Anixa Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/5/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
5/19/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/8/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/1/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
4/21/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
4/8/2026	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
4/8/2026	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
3/31/2026	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
3/25/2026	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00

(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	435.78	N/A	N/A	$0.39 per share	6.90
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A
SXTC China SXT Pharmaceuticals	$1.74M	48.76	N/A	N/A	$3,187.45 per share	0.00
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.31	N/A	N/A	N/A	N/A	-71.12%	-62.88%	N/A
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	6/22/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	-$10.41M	-$0.29	N/A	N/A	N/A	N/A	-201.23%	-172.71%	9/2/2026 (Estimated)

Latest NRSN, TELO, SXTC, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/30/2026	N/A	NRSN NeuroSense Therapeutics	-$0.1950	N/A	N/A	N/A	$0.27 million	N/A
6/10/2026	Q2 2026	ANIX Anixa Biosciences	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
5/14/2026	Q1 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.03	+$0.04	-$0.03	N/A	N/A
3/17/2026	Q4 2025	TELO Telomir Pharmaceuticals	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	9.79	9.79
NRSN NeuroSense Therapeutics	N/A	0.31	0.31
SXTC China SXT Pharmaceuticals	N/A	4.37	4.24
TELO Telomir Pharmaceuticals	N/A	7.00	7.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
NRSN NeuroSense Therapeutics	1.04%
SXTC China SXT Pharmaceuticals	5.02%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
NRSN NeuroSense Therapeutics	27.40%
SXTC China SXT Pharmaceuticals	3.95%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	34.02 million	25.04 million	Optionable
NRSN NeuroSense Therapeutics	10	32.56 million	23.64 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	38.22 million	36.71 million	Not Optionable
TELO Telomir Pharmaceuticals	1	68.78 million	N/A	N/A

NRSN, TELO, SXTC, and ANIX Headlines

Recent News About These Companies

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15 at 12:54 PM | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15 at 8:50 AM | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15 at 8:00 AM | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn

April 30, 2026 | tipranks.com

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

April 24, 2026 | usatoday.com

Telomir Pharmaceuticals Inc.

April 2, 2026 | barrons.com

Telomir seeks FDA approval for Telomir-1 to treat breast cancer

April 2, 2026 | msn.com

Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance

March 31, 2026 | tipranks.com

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

March 31, 2026 | accessnewswire.comA

Telomir Shareholders Approve Equity Plan and Bylaw Changes

March 27, 2026 | tipranks.com

Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines

February 21, 2026 | aktiencheck.deA

Telomir Sets Vote on Transformative TELI Merger and Governance Changes

February 19, 2026 | tipranks.com

Telomir reveals promising preclinical data for Telomir-Zn

February 17, 2026 | tipranks.com

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

February 17, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, TELO, SXTC, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.69 +0.08 (+3.07%)

As of 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

NeuroSense Therapeutics NASDAQ:NRSN

$0.70 +0.01 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 +0.04 (+4.96%)

As of 07:55 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.22 -0.10 (-4.31%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 +0.04 (+1.62%)

As of 06:13 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Telomir Pharmaceuticals NASDAQ:TELO

$1.25 -0.03 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.30 +0.05 (+4.40%)

As of 07:53 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, TELO, SXTC, and ANIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, TELO, SXTC, and ANIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, TELO, SXTC, and ANIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, TELO, SXTC, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

NeuroSense Therapeutics NASDAQ:NRSN

China SXT Pharmaceuticals NASDAQ:SXTC

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRSN, TELO, SXTC, and ANIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRSN, TELO, SXTC, and ANIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRSN, TELO, SXTC, and ANIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN, TELO, SXTC, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

NeuroSense Therapeutics NASDAQ:NRSN

China SXT Pharmaceuticals NASDAQ:SXTC

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools